{"id":"https://openalex.org/W7166807712","doi":"https://doi.org/10.1158/1078-0432.c.8568742","title":"Data from ZW191, an FR\u03b1-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile","display_name":"Data from ZW191, an FR\u03b1-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile","publication_year":2026,"publication_date":"2026-07-01","ids":{"openalex":"https://openalex.org/W7166807712","doi":"https://doi.org/10.1158/1078-0432.c.8568742"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.8568742","doi":"https://doi.org/10.1158/1078-0432.c.8568742","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8568742","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.8568742","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011615044","display_name":"Samuel O. Lawn","orcid":"https://orcid.org/0009-0005-8033-6990","observed_orcids":["https://orcid.org/0009-0005-8033-6990"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Samuel Lawn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-8033-6990","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056200860","display_name":"Andrea Hern\u00e1ndez Rojas","orcid":"https://orcid.org/0000-0002-0278-9434","observed_orcids":["https://orcid.org/0000-0002-0278-9434"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrea Hernandez Rojas","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0278-9434","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031726220","display_name":"Jodi Wong","orcid":"https://orcid.org/0009-0004-8505-2690","observed_orcids":["https://orcid.org/0009-0004-8505-2690"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jodi Wong","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-8505-2690","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089356754","display_name":"Lemlem T. Degefie","orcid":"https://orcid.org/0000-0001-6927-8973","observed_orcids":["https://orcid.org/0000-0001-6927-8973"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lemlem Degefie","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6927-8973","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020692464","display_name":"Araba Sagoe-Wagner","orcid":"https://orcid.org/0009-0004-9797-1440","observed_orcids":["https://orcid.org/0009-0004-9797-1440"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Araba Sagoe-Wagner","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-9797-1440","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087203944","display_name":"Ambroise Wu","orcid":"https://orcid.org/0000-0001-8568-8331","observed_orcids":["https://orcid.org/0000-0001-8568-8331"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ambroise Wu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8568-8331","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092122798","display_name":"Allysha Bissessur","orcid":"https://orcid.org/0009-0007-7597-3500","observed_orcids":["https://orcid.org/0009-0007-7597-3500"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Allysha Bissessur","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-7597-3500","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5117230793","display_name":"Matthew Bonderud","orcid":"https://orcid.org/0009-0005-1424-7295","observed_orcids":["https://orcid.org/0009-0005-1424-7295"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew Bonderud","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-1424-7295","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033698777","display_name":"Kaylee J. Wu","orcid":"https://orcid.org/0009-0009-6827-5960","observed_orcids":["https://orcid.org/0009-0009-6827-5960"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kaylee Wu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-6827-5960","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042018789","display_name":"D.A. Alonzo","orcid":"https://orcid.org/0000-0002-3586-3485","observed_orcids":["https://orcid.org/0000-0002-3586-3485"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diego Alonzo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3586-3485","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066470591","display_name":"Samir Das","orcid":"https://orcid.org/0000-0003-0615-5647","observed_orcids":["https://orcid.org/0000-0003-0615-5647"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Samir Das","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0615-5647","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5139748591","display_name":"Peter Chan","orcid":"https://orcid.org/0009-0000-4518-2328","observed_orcids":["https://orcid.org/0009-0000-4518-2328"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Chan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-4518-2328","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065872876","display_name":"Vincent Fung","orcid":"https://orcid.org/0009-0003-8513-0591","observed_orcids":["https://orcid.org/0009-0003-8513-0591"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vincent Fung","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0003-8513-0591","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071882607","display_name":"Luying Yang","orcid":"https://orcid.org/0009-0002-3732-2364","observed_orcids":["https://orcid.org/0009-0002-3732-2364"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Luying Yang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-3732-2364","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110089136","display_name":"Geoffrey C. Winters","orcid":"https://orcid.org/0009-0002-1235-1564","observed_orcids":["https://orcid.org/0009-0002-1235-1564"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geoffrey C. Winters","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-1235-1564","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020324790","display_name":"Kurt Stahl","orcid":"https://orcid.org/0009-0001-7230-6856","observed_orcids":["https://orcid.org/0009-0001-7230-6856"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kurt Stahl","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-7230-6856","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072941072","display_name":"Dunja Urosev","orcid":"https://orcid.org/0009-0002-6679-028X","observed_orcids":["https://orcid.org/0009-0002-6679-028X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dunja Urosev","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-6679-028X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5134011640","display_name":"Kari Frantzen","orcid":"https://orcid.org/0009-0009-4550-7765","observed_orcids":["https://orcid.org/0009-0009-4550-7765"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kari Frantzen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-4550-7765","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023294934","display_name":"Paul A. Moore","orcid":"https://orcid.org/0000-0001-6057-7539","observed_orcids":["https://orcid.org/0000-0001-6057-7539"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul A. Moore","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6057-7539","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020780697","display_name":"Raffaele Colombo","orcid":"https://orcid.org/0000-0001-5709-4704","observed_orcids":["https://orcid.org/0000-0001-5709-4704"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raffaele Colombo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5709-4704","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069995028","display_name":"Stuart D. Barnscher","orcid":"https://orcid.org/0009-0000-2386-5240","observed_orcids":["https://orcid.org/0009-0000-2386-5240"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stuart D. Barnscher","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-2386-5240","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5069149184","display_name":"Jamie R. Rich","orcid":"https://orcid.org/0009-0008-0926-1318","observed_orcids":["https://orcid.org/0009-0008-0926-1318"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jamie R. Rich","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-0926-1318","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8442000150680542,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8442000150680542,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.0364999994635582,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.020400000736117363,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9300000071525574},{"id":"https://openalex.org/keywords/folate-receptor-alpha","display_name":"folate receptor alpha","score":0.8809999823570251},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.8059999942779541},{"id":"https://openalex.org/keywords/mirvetuximab-soravtansine","display_name":"mirvetuximab soravtansine","score":0.9599999785423279},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.8040000200271606},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9819999933242798},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":1.0},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8989999890327454},{"id":"https://openalex.org/keywords/antibody-internalization","display_name":"antibody internalization","score":0.675000011920929},{"id":"https://openalex.org/keywords/bystander-effect","display_name":"bystander effect","score":0.7229999899864197},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6140000224113464},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.6970000267028809}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8614000082015991},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6506999731063843},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.5491999983787537},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.448199987411499},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4465000033378601},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42559999227523804},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4228000044822693},{"id":"https://openalex.org/C149172746","wikidata":"https://www.wikidata.org/wiki/Q2585693","display_name":"Efficacy","level":3,"score":0.3935999870300293},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.36970001459121704},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.36399999260902405},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.35569998621940613},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3402999937534332},{"id":"https://openalex.org/C2779682216","wikidata":"https://www.wikidata.org/wiki/Q419964","display_name":"Camptothecin","level":2,"score":0.33880001306533813},{"id":"https://openalex.org/C19106626","wikidata":"https://www.wikidata.org/wiki/Q230749","display_name":"Bystander effect","level":2,"score":0.33219999074935913},{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.3319999873638153},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.3203999996185303},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.30630001425743103},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.3059000074863434},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.2992999851703644},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29159998893737793},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2892000079154968},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.2808000147342682},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.2777999937534332},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.266400009393692},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.26339998841285706},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.25459998846054077},{"id":"https://openalex.org/C2992053201","wikidata":"https://www.wikidata.org/wiki/Q2585693","display_name":"Clinical efficacy","level":2,"score":0.2513999938964844}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.8568742","doi":"https://doi.org/10.1158/1078-0432.c.8568742","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8568742","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.8568742","doi":"https://doi.org/10.1158/1078-0432.c.8568742","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8568742","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7154941024","https://openalex.org/W7149013471","https://openalex.org/W4393085675","https://openalex.org/W4362536143","https://openalex.org/W4411642948","https://openalex.org/W7167021694","https://openalex.org/W7154698598","https://openalex.org/W4409820732","https://openalex.org/W4362534529","https://openalex.org/W4365511822"],"abstract_inverted_index":{"AbstractPurpose:":[0],"Multiple":[1],"antibody\u2013drug":[2],"conjugates":[3],"(ADC)":[4],"are":[5],"approved":[6],"for":[7,18,216],"the":[8,44,92,248],"treatment":[9],"of":[10,61,73,109,116],"human":[11],"cancers,":[12],"yet":[13],"there":[14],"remains":[15],"significant":[16],"potential":[17],"design":[19],"improvements":[20],"through":[21,153],"iterative":[22],"learnings":[23],"from":[24,210],"nonclinical":[25,56],"and":[26,41,58,67,76,86,106,125,137,151,184,227,245],"clinical":[27,212,236],"experience.":[28],"ZW191":[29,62,80,170,222,240],"is":[30,138,171,198,232],"a":[31,35,82,211],"clinical-stage":[32,143],"ADC":[33,95,144,205],"bearing":[34],"novel":[36,130,158],"topoisomerase":[37],"I":[38],"inhibitor":[39],"payload":[40,77,149,159],"targeted":[42],"to":[43,140,200,241],"clinically":[45,178],"validated":[46],"tumor":[47,155],"antigen":[48],"folate":[49],"receptor":[50],"\u03b1":[51],"(FR\u03b1).":[52],"Experimental":[53],"Design:":[54],"The":[55],"activity":[57,100,163],"tolerability":[59,87,188],"profiles":[60],"were":[63],"assessed":[64],"in":[65,68,98,101,111,146,164,173,175,190,219],"vitro":[66],"vivo,":[69],"focusing":[70],"on":[71,91],"properties":[72,136],"its":[74,99,147,201],"antibody":[75,132],"components.":[78],"Results:":[79],"has":[81],"highly":[83],"differentiated":[84,230],"efficacy":[85,226],"profile,":[88],"markedly":[89],"improving":[90],"FDA-approved":[93],"FR\u03b1-targeted":[94],"mirvetuximab":[96],"soravtansine":[97],"tumors":[102],"with":[103,177],"both":[104],"high":[105],"low":[107],"levels":[108],"FR\u03b1":[110],"multiple":[112,141],"patient-derived":[113],"xenograft":[114],"models":[115],"ovarian":[117],"cancer,":[118,120,124],"endometrial":[119],"non\u2013small":[121],"cell":[122],"lung":[123],"triple-negative":[126],"breast":[127],"cancer.":[128],"ZW191\u2019s":[129,157,186],"FR\u03b1-targeting":[131],"demonstrates":[133,223],"unique":[134],"binding":[135],"superior":[139],"other":[142],"antibodies":[145],"internalization,":[148],"delivery,":[150],"penetration":[152],"3D":[154],"spheroids.":[156],"drives":[160],"strong":[161],"antitumor":[162],"vitro,":[165],"including":[166],"bystander":[167],"activity.":[168],"Furthermore,":[169],"effective":[172],"vivo":[174],"combination":[176],"relevant":[179],"standard-of-care":[180,253],"drugs":[181],"carboplatin,":[182],"bevacizumab,":[183],"paclitaxel.":[185],"best-in-class":[187],"profile":[189,231],"Good":[191],"Laboratory":[192],"Practice":[193],"nonhuman":[194],"primate":[195],"toxicity":[196],"studies":[197],"owing":[199],"payload\u2019s":[202],"moderate":[203],"potency\u2014an":[204],"feature":[206],"that":[207],"we":[208],"show":[209],"landscape":[213],"analysis":[214],"allows":[215],"higher":[217],"dosing":[218],"humans.":[220],"Conclusions:":[221],"favorable":[224],"preclinical":[225],"tolerability.":[228],"This":[229],"supported":[233],"by":[234],"initial":[235],"data,":[237],"potentially":[238],"positioning":[239],"meaningfully":[242],"improve":[243],"responses":[244],"substantially":[246],"widen":[247],"targetable":[249],"patient":[250],"population":[251],"over":[252],"treatment.":[254]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2026-07-02T00:00:00"}